Back to top
more

AngioDynamics (ANGO)

(Delayed Data from NSDQ)

$5.81 USD

5.81
313,347

+0.03 (0.52%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $5.80 -0.01 (-0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for ANGO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for AngioDynamics, Inc falls in the month of May.

All items in Millions except Per Share data.

5/31/2023 5/31/2022 5/31/2021 5/31/2020 5/31/2019
Assets          
Cash & Equivalents 45 29 48 54 228
Receivables 53 52 35 31 44
Notes Receivable 0 0 0 0 0
Inventories 55 51 49 60 40
Other Current Assets 11 11 9 7 4
Total Current Assets 164 143 141 153 315
Net Property & Equipment 44 45 37 28 24
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 270 353 370 398 493
Deposits & Other Assets 54 11 13 15 4
Total Assets 533 553 561 594 836
Liabilities & Shareholders Equity 5/31/2023 5/31/2022 5/31/2021 5/31/2020 5/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 40 28 20 19 23
Current Portion Long-Term Debt 0 0 0 0 8
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 27 35 35 29 38
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 17 11 3 3 5
Total Current Liabilities 84 74 58 51 73
Mortgages 0 0 0 0 0
Deferred Taxes/Income 13 16 20 24 15
Convertible Debt 0 0 0 0 0
Long-Term Debt 50 25 20 40 124
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 8 13 24 24 9
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 154 128 122 139 222
Shareholders Equity 5/31/2023 5/31/2022 5/31/2021 5/31/2020 5/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 599 587 574 562 555
Retained Earnings -211 -158 -132 -100 66
Other Equity -5 1 3 -1 -1
Treasury Stock 6 6 6 6 6
Total Shareholder's Equity 378 424 439 455 615
Total Liabilities & Shareholder's Equity 533 553 561 594 836
Total Common Equity 378 424 439 455 615
Shares Outstanding 39.20 38.70 38.10 37.60 37.20
Book Value Per Share 9.65 10.97 11.53 12.10 16.53

Fiscal Year End for AngioDynamics, Inc falls in the month of May.

All items in Millions except Per Share data.

2/29/2024 11/30/2023 8/31/2023 5/31/2023 2/28/2023
Assets          
Cash & Equivalents 78 61 58 45 30
Receivables 49 52 50 53 51
Notes Receivable 0 0 0 0 0
Inventories 58 64 60 55 64
Other Current Assets 11 9 8 11 8
Total Current Assets 197 185 175 164 153
Net Property & Equipment 37 43 43 44 46
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 82 263 266 270 334
Deposits & Other Assets 9 8 9 54 11
Total Assets 325 500 494 533 543
Liabilities & Shareholders Equity 2/29/2024 11/30/2023 8/31/2023 5/31/2023 2/28/2023
Notes Payable 0 0 0 0 0
Accounts Payable 35 38 25 40 36
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 31 29 26 27 22
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 20 11 7 17 12
Total Current Liabilities 86 78 57 84 70
Mortgages 0 0 0 0 0
Deferred Taxes/Income 6 18 1 13 13
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 50 50
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 14 7 8 12
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 106 98 66 154 145
Shareholders Equity 2/29/2024 11/30/2023 8/31/2023 5/31/2023 2/28/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 609 605 604 599 596
Retained Earnings -382 -194 -165 -211 -189
Other Equity -3 -5 -6 -5 -4
Treasury Stock 6 6 6 6 6
Total Shareholder's Equity 219 401 428 378 398
Total Liabilities & Shareholder's Equity 325 500 494 533 543
Total Common Equity 219 401 428 378 398
Shares Outstanding 39.80 39.80 39.80 39.20 39.20
Book Value Per Share 5.49 10.08 10.75 9.65 10.14